Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study

PURPOSE: Restoration of iodine incorporation (redifferentiation) by MAPK inhibition was achieved in previously radioiodine-refractory, unresectable thyroid carcinoma (RR-TC). However, results were unsatisfactory in BRAF(V600E)-mutant (BRAF-MUT) RR-TC. Here we assess safety and efficacy of redifferen...

Descripción completa

Detalles Bibliográficos
Autores principales: Weber, Manuel, Kersting, David, Riemann, Burkhard, Brandenburg, Tim, Führer-Sakel, Dagmar, Grünwald, Frank, Kreissl, Michael C., Dralle, Henning, Weber, Frank, Schmid, Kurt Werner, Herrmann, Ken, Jentzen, Walter, Grafe, Hong, Rischpler, Christoph, Theurer, Sarah, Bockisch, Andreas, Nagarajah, James, Fendler, Wolfgang P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527501/
https://www.ncbi.nlm.nih.gov/pubmed/35594174
http://dx.doi.org/10.1158/1078-0432.CCR-22-0437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527501/
https://www.ncbi.nlm.nih.gov/pubmed/35594174
http://dx.doi.org/10.1158/1078-0432.CCR-22-0437

Ejemplares similares